Neuroendocrine Tumor Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drugs (Everolimus, Suininib Malate, Lu-Dotate, Lanreotide and Octreotide); Indication (Gastrointestinal NET, Lung NET, Pancreatic NET, And Others NET); End User (Hospitals, Oncology Centers , Others) and Geography

Report Code: TIPRE00003843 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET OVERVIEW

Neuroendocrine tumors are the maliganancies that starts in specialized cells called neuroendocrine cells. Neuroendocrine cells have traits and characteristics similar to those of hormone-producing cells and nerve cells. Neuroendocrine tumours are rare and can develop in any part of the body. The lungs, appendix, small intestine, rectum, and pancreas are the most major areas for neuroendocrine tumours. The treatment options for neuroendocrine tumors are, chemotherapy, surgery and radiation therapy.

MARKET SCOPE

The "Global Neuroendocrine Tumor Treatment Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the neuroendocrine tumor treatment market with detailed market segmentation by drugs, indication and end-user. The report provides key statistics on the market status of the leading neuroendocrine tumor treatment market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

  •   Based on drugs the market is segmented as, Everolimus, Suininib Malate, Lu-Dotate, Lanreotide and Octreotide.
  •   Based on indication the market is segmented as, Gastrointestinal NET, Lung NET, Pancreatic NET, and Others NET.
  •   Based on end user the market is segmented as, Hospitals, Oncology Centers and Others.

MARKET DYNAMICS
Drivers:

  •   Increasing prevalence of neuroendocrine cancers is the key driving factor for the market growth.
  •   Rising screening activities to detect cancers at early stage for better outlook of disease is also expected to spur the market growth.
  •   Presence of advanced diagnostic imaging tests, advancement in healthcare infrastructure are likely to boost market growth.
  •   Extensive R&D activities to develop novel and targeted therapies for management of NET.

Restraints:

  •   However, high cost of NET treatment and risk of side effects after treatment are expected to restrain market growth during the forecast period.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The neuroendocrine tumor treatment market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the neuroendocrine tumor treatment market in these regions.

IMPACT OF COVID-19 ON NEUROENDOCRINE TUMOR TREATMENT MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. There is big shift in demand for neuroendocrine tumor treatment drugs and therapeutics because of pandemic situation and lockdown scenes so that people cannot come out from their homes and can't take their cancer treatments which ultimately affecting the demand for neuroendocrine tumor treatment and drugs . According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.

MARKET PLAYERS

The report covers key developments in the neuroendocrine tumor treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from neuroendocrine tumor treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for neuroendocrine tumor treatment in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the neuroendocrine tumor treatment market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •   Pfizer Inc.
  •   Novartis AG
  •   Ipsen Pharma
  •   Advanced Accelerator Applications
  •   Tarveda Therapeutics
  •   Lantheus Medical Imaging, Inc
  •   HUTCHMED
  •   Dauntless Pharmaceuticals
  •   Exelixis, Inc
  •   AVEO Oncology
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Neuroendocrine Tumor Treatment Market - By Drugs
1.3.2 Neuroendocrine Tumor Treatment Market - By Indication
1.3.3 Neuroendocrine Tumor Treatment Market - By End User
1.3.4 Neuroendocrine Tumor Treatment Market - By Region
1.3.4.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. NEUROENDOCRINE TUMOR TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS

5. NEUROENDOCRINE TUMOR TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. NEUROENDOCRINE TUMOR TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. NEUROENDOCRINE TUMOR TREATMENT - GLOBAL MARKET OVERVIEW
6.2. NEUROENDOCRINE TUMOR TREATMENT - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE

7. NEUROENDOCRINE TUMOR TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DRUGS
7.1. OVERVIEW
7.2. DRUGS MARKET FORECASTS AND ANALYSIS
7.3. EVEROLIMUS
7.3.1. Overview
7.3.2. Everolimus Market Forecast and Analysis
7.4. SUININIB MALATE
7.4.1. Overview
7.4.2. Suininib Malate Market Forecast and Analysis
7.5. LU-DOTATE
7.5.1. Overview
7.5.2. Lu-Dotate Market Forecast and Analysis
7.6. LANREOTIDE AND OCTREOTIDE
7.6.1. Overview
7.6.2. Lanreotide and Octreotide Market Forecast and Analysis
8. NEUROENDOCRINE TUMOR TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - INDICATION
8.1. OVERVIEW
8.2. INDICATION MARKET FORECASTS AND ANALYSIS
8.3. GASTROINTESTINAL NET
8.3.1. Overview
8.3.2. Gastrointestinal NET Market Forecast and Analysis
8.4. LUNG NET
8.4.1. Overview
8.4.2. Lung NET Market Forecast and Analysis
8.5. PANCREATIC NET
8.5.1. Overview
8.5.2. Pancreatic NET Market Forecast and Analysis
8.6. AND OTHERS NET
8.6.1. Overview
8.6.2. and Others NET Market Forecast and Analysis
9. NEUROENDOCRINE TUMOR TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. ONCOLOGY CENTERS
9.4.1. Overview
9.4.2. Oncology Centers Market Forecast and Analysis
9.5. OTHERS
9.5.1. Overview
9.5.2. Others Market Forecast and Analysis

10. NEUROENDOCRINE TUMOR TREATMENT MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Neuroendocrine Tumor Treatment Market Overview
10.1.2 North America Neuroendocrine Tumor Treatment Market Forecasts and Analysis
10.1.3 North America Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Drugs
10.1.4 North America Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Indication
10.1.5 North America Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By End User
10.1.6 North America Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Countries
10.1.6.1 United States Neuroendocrine Tumor Treatment Market
10.1.6.1.1 United States Neuroendocrine Tumor Treatment Market by Drugs
10.1.6.1.2 United States Neuroendocrine Tumor Treatment Market by Indication
10.1.6.1.3 United States Neuroendocrine Tumor Treatment Market by End User
10.1.6.2 Canada Neuroendocrine Tumor Treatment Market
10.1.6.2.1 Canada Neuroendocrine Tumor Treatment Market by Drugs
10.1.6.2.2 Canada Neuroendocrine Tumor Treatment Market by Indication
10.1.6.2.3 Canada Neuroendocrine Tumor Treatment Market by End User
10.1.6.3 Mexico Neuroendocrine Tumor Treatment Market
10.1.6.3.1 Mexico Neuroendocrine Tumor Treatment Market by Drugs
10.1.6.3.2 Mexico Neuroendocrine Tumor Treatment Market by Indication
10.1.6.3.3 Mexico Neuroendocrine Tumor Treatment Market by End User
10.1.6.4 US Neuroendocrine Tumor Treatment Market
10.1.6.4.1 US Neuroendocrine Tumor Treatment Market by Drugs
10.1.6.4.2 US Neuroendocrine Tumor Treatment Market by Indication
10.1.6.4.3 US Neuroendocrine Tumor Treatment Market by End User
10.2. EUROPE
10.2.1 Europe Neuroendocrine Tumor Treatment Market Overview
10.2.2 Europe Neuroendocrine Tumor Treatment Market Forecasts and Analysis
10.2.3 Europe Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Drugs
10.2.4 Europe Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Indication
10.2.5 Europe Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By End User
10.2.6 Europe Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Neuroendocrine Tumor Treatment Market
10.2.6.1.1 Germany Neuroendocrine Tumor Treatment Market by Drugs
10.2.6.1.2 Germany Neuroendocrine Tumor Treatment Market by Indication
10.2.6.1.3 Germany Neuroendocrine Tumor Treatment Market by End User
10.2.6.2 France Neuroendocrine Tumor Treatment Market
10.2.6.2.1 France Neuroendocrine Tumor Treatment Market by Drugs
10.2.6.2.2 France Neuroendocrine Tumor Treatment Market by Indication
10.2.6.2.3 France Neuroendocrine Tumor Treatment Market by End User
10.2.6.3 Italy Neuroendocrine Tumor Treatment Market
10.2.6.3.1 Italy Neuroendocrine Tumor Treatment Market by Drugs
10.2.6.3.2 Italy Neuroendocrine Tumor Treatment Market by Indication
10.2.6.3.3 Italy Neuroendocrine Tumor Treatment Market by End User
10.2.6.4 Spain Neuroendocrine Tumor Treatment Market
10.2.6.4.1 Spain Neuroendocrine Tumor Treatment Market by Drugs
10.2.6.4.2 Spain Neuroendocrine Tumor Treatment Market by Indication
10.2.6.4.3 Spain Neuroendocrine Tumor Treatment Market by End User
10.2.6.5 United Kingdom Neuroendocrine Tumor Treatment Market
10.2.6.5.1 United Kingdom Neuroendocrine Tumor Treatment Market by Drugs
10.2.6.5.2 United Kingdom Neuroendocrine Tumor Treatment Market by Indication
10.2.6.5.3 United Kingdom Neuroendocrine Tumor Treatment Market by End User
10.2.6.6 Rest of Europe Neuroendocrine Tumor Treatment Market
10.2.6.6.1 Rest of Europe Neuroendocrine Tumor Treatment Market by Drugs
10.2.6.6.2 Rest of Europe Neuroendocrine Tumor Treatment Market by Indication
10.2.6.6.3 Rest of Europe Neuroendocrine Tumor Treatment Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Neuroendocrine Tumor Treatment Market Overview
10.3.2 Asia-Pacific Neuroendocrine Tumor Treatment Market Forecasts and Analysis
10.3.3 Asia-Pacific Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Drugs
10.3.4 Asia-Pacific Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Indication
10.3.5 Asia-Pacific Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Neuroendocrine Tumor Treatment Market
10.3.6.1.1 Australia Neuroendocrine Tumor Treatment Market by Drugs
10.3.6.1.2 Australia Neuroendocrine Tumor Treatment Market by Indication
10.3.6.1.3 Australia Neuroendocrine Tumor Treatment Market by End User
10.3.6.2 China Neuroendocrine Tumor Treatment Market
10.3.6.2.1 China Neuroendocrine Tumor Treatment Market by Drugs
10.3.6.2.2 China Neuroendocrine Tumor Treatment Market by Indication
10.3.6.2.3 China Neuroendocrine Tumor Treatment Market by End User
10.3.6.3 India Neuroendocrine Tumor Treatment Market
10.3.6.3.1 India Neuroendocrine Tumor Treatment Market by Drugs
10.3.6.3.2 India Neuroendocrine Tumor Treatment Market by Indication
10.3.6.3.3 India Neuroendocrine Tumor Treatment Market by End User
10.3.6.4 Japan Neuroendocrine Tumor Treatment Market
10.3.6.4.1 Japan Neuroendocrine Tumor Treatment Market by Drugs
10.3.6.4.2 Japan Neuroendocrine Tumor Treatment Market by Indication
10.3.6.4.3 Japan Neuroendocrine Tumor Treatment Market by End User
10.3.6.5 Rest of Asia-Pacific Neuroendocrine Tumor Treatment Market
10.3.6.5.1 Rest of Asia-Pacific Neuroendocrine Tumor Treatment Market by Drugs
10.3.6.5.2 Rest of Asia-Pacific Neuroendocrine Tumor Treatment Market by Indication
10.3.6.5.3 Rest of Asia-Pacific Neuroendocrine Tumor Treatment Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Neuroendocrine Tumor Treatment Market Overview
10.4.2 Middle East and Africa Neuroendocrine Tumor Treatment Market Forecasts and Analysis
10.4.3 Middle East and Africa Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Drugs
10.4.4 Middle East and Africa Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Indication
10.4.5 Middle East and Africa Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Neuroendocrine Tumor Treatment Market
10.4.6.1.1 South Africa Neuroendocrine Tumor Treatment Market by Drugs
10.4.6.1.2 South Africa Neuroendocrine Tumor Treatment Market by Indication
10.4.6.1.3 South Africa Neuroendocrine Tumor Treatment Market by End User
10.4.6.2 Saudi Arabia Neuroendocrine Tumor Treatment Market
10.4.6.2.1 Saudi Arabia Neuroendocrine Tumor Treatment Market by Drugs
10.4.6.2.2 Saudi Arabia Neuroendocrine Tumor Treatment Market by Indication
10.4.6.2.3 Saudi Arabia Neuroendocrine Tumor Treatment Market by End User
10.4.6.3 U.A.E Neuroendocrine Tumor Treatment Market
10.4.6.3.1 U.A.E Neuroendocrine Tumor Treatment Market by Drugs
10.4.6.3.2 U.A.E Neuroendocrine Tumor Treatment Market by Indication
10.4.6.3.3 U.A.E Neuroendocrine Tumor Treatment Market by End User
10.4.6.4 Rest of Middle East and Africa Neuroendocrine Tumor Treatment Market
10.4.6.4.1 Rest of Middle East and Africa Neuroendocrine Tumor Treatment Market by Drugs
10.4.6.4.2 Rest of Middle East and Africa Neuroendocrine Tumor Treatment Market by Indication
10.4.6.4.3 Rest of Middle East and Africa Neuroendocrine Tumor Treatment Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Neuroendocrine Tumor Treatment Market Overview
10.5.2 South and Central America Neuroendocrine Tumor Treatment Market Forecasts and Analysis
10.5.3 South and Central America Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Drugs
10.5.4 South and Central America Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Indication
10.5.5 South and Central America Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By End User
10.5.6 South and Central America Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Neuroendocrine Tumor Treatment Market
10.5.6.1.1 Brazil Neuroendocrine Tumor Treatment Market by Drugs
10.5.6.1.2 Brazil Neuroendocrine Tumor Treatment Market by Indication
10.5.6.1.3 Brazil Neuroendocrine Tumor Treatment Market by End User
10.5.6.2 Argentina Neuroendocrine Tumor Treatment Market
10.5.6.2.1 Argentina Neuroendocrine Tumor Treatment Market by Drugs
10.5.6.2.2 Argentina Neuroendocrine Tumor Treatment Market by Indication
10.5.6.2.3 Argentina Neuroendocrine Tumor Treatment Market by End User
10.5.6.3 Rest of South and Central America Neuroendocrine Tumor Treatment Market
10.5.6.3.1 Rest of South and Central America Neuroendocrine Tumor Treatment Market by Drugs
10.5.6.3.2 Rest of South and Central America Neuroendocrine Tumor Treatment Market by Indication
10.5.6.3.3 Rest of South and Central America Neuroendocrine Tumor Treatment Market by End User

11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

12. NEUROENDOCRINE TUMOR TREATMENT MARKET, KEY COMPANY PROFILES
12.1. PFIZER INC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. NOVARTIS AG
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. IPSEN PHARMA
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ADVANCED ACCELERATOR APPLICATIONS
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. TARVEDA THERAPEUTICS
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. LANTHEUS MEDICAL IMAGING, INC
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. HUTCHMED
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. DAUNTLESS PHARMACEUTICALS
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. EXELIXIS, INC
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. AVEO ONCOLOGY
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments

13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
"
The List of Companies

1. Pfizer Inc.
2. Novartis AG
3. Ipsen Pharma
4. Advanced Accelerator Applications
5. Tarveda Therapeutics
6. Lantheus Medical Imaging, Inc
7. HUTCHMED
8. Dauntless Pharmaceuticals
9. Exelixis, Inc
10. AVEO Oncology
TIPRE00003843
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking